117 related articles for article (PubMed ID: 8402611)
1. Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis.
Srivastava S; Wang S; Tong YA; Hao ZM; Chang EH
Cancer Res; 1993 Oct; 53(19):4452-5. PubMed ID: 8402611
[TBL] [Abstract][Full Text] [Related]
2. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
3. Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Tong YA; Devadas K; Zou ZQ; Sykes VW; Chen Y; Blattner WA; Pirollo K; Chang EH
Oncogene; 1992 May; 7(5):987-91. PubMed ID: 1373881
[TBL] [Abstract][Full Text] [Related]
4. A germline 2.35 kb deletion of p53 genomic DNA creating a specific loss of the oligomerization domain inherited in a Li-Fraumeni syndrome family.
Plummer SJ; Santibáñez-Koref M; Kurosaki T; Liao S; Noble B; Fain PR; Anton-Culver H; Casey G
Oncogene; 1994 Nov; 9(11):3273-80. PubMed ID: 7936651
[TBL] [Abstract][Full Text] [Related]
5. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
6. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
[TBL] [Abstract][Full Text] [Related]
7. Germ-line exclusion of a single p53 allele by premature termination of translation in a Li-Fraumeni syndrome family.
Stolzenberg MC; Brugières L; Gardes M; Dessarps-Freichey F; Chompret A; Bressac B; Lenoir G; Bonaïti-Pellié C; Lemerle J; Feunteun J
Oncogene; 1994 Oct; 9(10):2799-804. PubMed ID: 8084585
[TBL] [Abstract][Full Text] [Related]
8. Complex replication error causes p53 mutation in a Li-Fraumeni family.
Strauss EA; Hosler MR; Herzog P; Salhany K; Louie R; Felix CA
Cancer Res; 1995 Aug; 55(15):3237-41. PubMed ID: 7614454
[TBL] [Abstract][Full Text] [Related]
9. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
[TBL] [Abstract][Full Text] [Related]
10. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome.
Srivastava S; Zou ZQ; Pirollo K; Blattner W; Chang EH
Nature; 1990 Dec 20-27; 348(6303):747-9. PubMed ID: 2259385
[TBL] [Abstract][Full Text] [Related]
11. [Li-Fraumeni syndrome and germ-line mutations of the p53 gene].
Leblanc T; Soussi T
Arch Pediatr; 1994 Jan; 1(1):61-70. PubMed ID: 8087224
[TBL] [Abstract][Full Text] [Related]
12. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation.
Capponcelli S; Pedrini E; Cerone MA; Corti V; Fontanesi S; Alessio M; Bachi A; Soddu S; Ribatti D; Picci P; Helman LJ; Cantelli-Forti G; Sangiorgi L
Hum Mutat; 2005 Aug; 26(2):94-103. PubMed ID: 15977174
[TBL] [Abstract][Full Text] [Related]
14. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
15. p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.
Quesnel S; Verselis S; Portwine C; Garber J; White M; Feunteun J; Malkin D; Li FP
Oncogene; 1999 Jul; 18(27):3970-8. PubMed ID: 10435620
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population.
Yamada H; Shinmura K; Okudela K; Goto M; Suzuki M; Kuriki K; Tsuneyoshi T; Sugimura H
Carcinogenesis; 2007 Sep; 28(9):2013-8. PubMed ID: 17690113
[TBL] [Abstract][Full Text] [Related]
17. In vitro transformation of Li-Fraumeni syndrome fibroblasts by SV40 large T antigen mutants.
Maclean K; Rogan EM; Whitaker NJ; Chang AC; Rowe PB; Dalla-Pozza L; Symonds G; Reddel RR
Oncogene; 1994 Mar; 9(3):719-25. PubMed ID: 8108114
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome.
Davison TS; Yin P; Nie E; Kay C; Arrowsmith CH
Oncogene; 1998 Aug; 17(5):651-6. PubMed ID: 9704931
[TBL] [Abstract][Full Text] [Related]
19. A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm.
Felix CA; Strauss EA; D'Amico D; Tsokos M; Winter S; Mitsudomi T; Nau MM; Brown DL; Leahey AM; Horowitz ME
Oncogene; 1993 May; 8(5):1203-10. PubMed ID: 8479743
[TBL] [Abstract][Full Text] [Related]
20. A functionally inactive p53 Li-Fraumeni syndrome mutant.
Hao M; Finlay CA; Lozano G
Oncogene; 1993 Feb; 8(2):299-306. PubMed ID: 8426739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]